Rank
|
NCT No.
|
Title
|
Status
|
Conditions
|
Interventions
|
Phases
|
Enrollment
|
1
|
04889768
|
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
|
Not yet recruiting
|
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
|
Drug: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
|
Not Applicable
|
46
|
2
|
04286711
|
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
|
Not yet recruiting
|
Advanced Gastric Cancer
|
Drug: Albumin-paclitaxel, Apatinib, Camrelizumab
|
Phase 1
Phase 2
|
52
|
3
|
04792515
|
Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
|
Recruiting
|
Locally Advanced Gastric Cancer
|
Drug: Camrelizumab combined with SOX/ or apatinib
|
Phase 2
|
67
|
4
|
04515615
|
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
|
Recruiting
|
Gastric Cancer Stage III
|
Drug: Camrelizumab
Drug: Oxaliplatin
Drug: Tegafur gimeracil oteracil potassium capsule
|
Phase 2
|
52
|
5
|
05101616
|
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
|
Not yet recruiting
|
Gastric Cancer
|
Drug: Camrelizumab+ chemotherapy
Drug: Chemotherapy
|
Phase 1
Phase 2
|
100
|
6
|
04182724
|
Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
|
Recruiting
|
Advanced Gastric Cancer
|
Drug: Camrelizumab, Apatinib and Nab-paclitaxel
|
Phase 1
Phase 2
|
57
|
7
|
04258644
|
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
|
Not yet recruiting
|
Gastric Cancer
|
Drug: Camrelizumab+ Apatinib+Paclitaxel-albumin+ S-1
|
Phase 2
|
30
|
8
|
04195828
|
Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
|
Recruiting
|
Advanced Gastric Cancer
|
Drug: Camrelizumab|Drug: Apatinib Mesylate|Drug: nab-paclitaxel|Drug: S1
|
Phase 2
|
53
|
9
|
04694183
|
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
|
Recruiting
|
Gastric Cancer
|
Drug: Paclitaxel + S-1 + anti-PD-1 antibody (Peritoneal metastasis)
Drug: SOX regimen + anti-PD-1 antibody (Liver metastasis, para-aortic lymph node metastasis )
|
Phase 2
|
60
|
10
|
04345783
|
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
|
Active, not recruiting
|
Gastric Cancer
|
Drug: Camrelizumab for injection, apatinib mesylate and tegio
|
Phase 2
|
30
|
11
|
05070598
|
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
|
Recruiting
|
HER2-positive Gastric Cancer
|
Drug: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
|
Phase 2
|
35
|
12
|
04152889
|
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
|
Recruiting
|
Gastric Cancer Stage III
|
Drug: Camrelizumab|Drug: S-1
Drug: Docetaxel
|
Phase 2
|
20
|
13
|
04609176
|
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
|
Recruiting
|
Gastric Cancer
|
Drug: Camrelizumab plus Apatinib and SOX
Drug: Camrelizumab plus Apatinib
|
Phase 2
|
117
|
14
|
05184946
|
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
|
Recruiting
|
Gastric Cancer
|
Drug: Camrelizumab Combined with SOX
|
Phase 2
|
72
|
15
|
05095636
|
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
|
Recruiting
|
Gastric Cancer
Metastasis
|
Drug: Apatinib Mesylate
Drug: Camrelizumab
|
Phase 2
|
102
|
16
|
04342910
|
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
|
Recruiting
|
Gastric Cancer
|
Drug: camrelizumab|Drug: Apatinib Mesylate
Drug: Paclitaxel|Drug: Irinotecan
|
Phase 3
|
550
|
17
|
04572542
|
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
|
Recruiting
|
Locally Advanced or Metastatic Gastric Adenocarcinoma
|
Drug: Camrelizumab
Drug: Apatinib Mesylate|Drug: nab-paclitaxel
|
Phase 1
Phase 2
|
46
|
18
|
04631757
|
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Not yet recruiting
|
Gastric Cancer
|
Drug: Camrelizumab + SOX + Radiotherapy
|
Phase 2
|
33
|
19
|
04067986
|
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
|
Recruiting
|
Colorectal Cancer Recurrent
|
Drug: Camrelizumab
Drug: Apatinib
|
Phase 1
Phase 2
|
62
|
20
|
04781686
|
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
|
Recruiting
|
Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
|
Drug: Camrelizumab
Drug: Apatinib Mesylate
Drug: S1
Drug: Docetaxel injection
|
Phase 2
|
35
|
21
|
04948125
|
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
|
Recruiting
|
Advanced Gastric Carcinoma
|
Drug: camrelizumab|Drug: Apatinib Mesylate
|
Phase 2
|
20
|
22
|
05111444
|
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Not yet recruiting
|
Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma
|
Drug: Camrelizumab
Drug: Pyrotinib
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: S-1
|
Phase 2
|
65
|
23
|
04510064
|
PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer
|
Recruiting
|
Metastatic Gastric Cancer
Locally Advanced Gastric Adenocarcinoma
|
Drug: Camrelizumab plus mFLOT regimen
Procedure: R0 surgery
|
Phase 2
|
40
|
24
|
03939962
|
Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma
|
Completed
|
Gastric Cancer
|
Drug: SHR1210 combined with FOLFOX
|
Phase 2
|
60
|
25
|
05170542
|
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
|
Recruiting
|
Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC
|
Drug: Camrelizumab+S-1
|
Phase 2
|
42
|
26
|
04675866
|
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
|
Recruiting
|
Advanced Gastric Adenocarcinoma
|
Other: Camrelizumab, Albumin-bound paclitaxel, S-1
|
Not Applicable
|
46
|
27
|
04508686
|
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
|
Recruiting
|
Advanced Cervical Cancer
|
Drug: Capecitabine, camrelizumab
|
Phase 1
|
20
|
28
|
04367025
|
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
|
Not yet recruiting
|
Gastric Cancer
|
Drug: Camrelizumab
Drug: Oxaliplatin
Drug: S1
|
Phase 2
|
70
|